Table 4.

Multivariate proportional hazards regression predicting treatment failure^*

		p-value	Hazard ratio	95% confidence interval
Age at diagnosis	Trend	0.14	–	–	–
	55–64 vs ≥65	0.22	0.73	0.45	1.21
	<55 vs ≥65	0.05	0.49	0.24	1.01
PSA at diagnosis	Trend	0.01	–	–	–
	4.1–6 vs ≥10.1	0.001	0.38	0.21	0.68
	6.1–10 vs ≥10.1	0.03	0.56	0.32	0.95
	<4 vs ≥10.1	0.20	0.57	0.24	1.35
Biopsy Gleason total	<7 vs ≥7	0.07	0.63	0.38	1.04
T-stage at diagnosis	cT1 vs cT2/3	0.91	0.97	0.61	1.56
Surgical margins	Negative vs positive	0.001	0.46	0.29	0.74
USPSA 4–12 wk post-RP	Undetectable vs detectable	<0.0001	0.33	0.20	0.55
Pathologic Gleason total	<7 vs ≥7	0.01	0.39	0.20	0.79
T-stage at pathology	pT2 vs pT3	0.001	0.48	0.30	0.75

PSA = prostate-specific antigen; USPSA = ultrasensitive prostate-specific antigen; RP = radical prostatectomy.

^*Failure defined as two consecutive PSA values ≥0.2 ng/ml or secondary treatment.